Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Log-galectin-3 (HR 1.05; 95% CI, 0.91, 1.22) and log-growth differentiation factor-15 (HR 1.16; 95% CI, 0.96, 1.40) were not significantly associated with incident AF.
|
31379242 |
2019 |
Atrial Fibrillation
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, patients with persistent or permanent AF had higher levels of Gal-3.
|
29861319 |
2019 |
Atrial Fibrillation
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Galectin-3 levels were lower in patients without AF (p < 0.01) than in those with permanent/persistent AF.
|
30726858 |
2019 |
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
The levels of myocardial fibrosis biomarkers, such as ST2 and Galectin-3, are elevated suggesting atrial structural abnormalities, while the increased levels of CRP and Interleukin-6 supplement the inflammatory profile of AF patients.
|
28875838 |
2019 |
Atrial Fibrillation
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Pooled results showed that baseline circulating Gal-3 levels were significantly higher in patients with AF recurrence compared to those without (standardized mean difference: 0.74; 95% confidence interval (CI): 0.21 - 1.27; p = 0.007; I<sup>2</sup> = 89%).
|
31772609 |
2019 |
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Galectin-3 level of the AMI group was higher than that of the unstable angina pectoris (UAP) group, and its levels were higher than that of the stable angina pectoris (SAP) group, the differences were statistically significant among both groups (P<0.05); Galectin-3 level of multivessel coronary disease group was higher than that of single vessel group, in which a statistically significant difference was noted (P<0.05); There was no statistically significant difference associated in the drop of Galectin-3 levels in patients with AMI after PCI (P>0.05); Galectin-3 of patients with AF decreased after RFCA, but no statistical significance noted (P>0.05); Galectin-3 was negatively correlated with the LVEF value(r=-0.405, P<0.05).
|
29287900 |
2018 |
Atrial Fibrillation
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We aimed to investigate whether the change in serum Gal-3 reflects alterations of the arrhythmogenic atrial substrate following thoracoscopic AF surgery, and predicts absence of AF.
|
28525549 |
2018 |
Atrial Fibrillation
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, Gal-3 levels in coronary sinus blood samples and myocardial Gal-3 expression levels were higher in the PeAF patients than in the SR patients, and higher level profibrotic pathway activation was also confirmed.
|
29807358 |
2018 |
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
We sought to find whether galectin-3 has a prognostic value in patients with heart failure and a reduced left ventricular ejection fraction undergoing ablation of persistent atrial fibrillation.
|
30067817 |
2018 |
Atrial Fibrillation
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Galectin-3 expression was significantly higher in EAT than in SAT or PAT (P < 0.001), with no significant differences between patients with AF and SR (P > 0.05).
|
29483593 |
2018 |
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Galectin-3 in Atrial Fibrillation: Mechanisms and Therapeutic Implications.
|
29587379 |
2018 |
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Elevated plasma galectin-3 is associated with increased risk of incident AF.
|
28938960 |
2017 |
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Galectin-3 is a biomarker reflecting pro-inflammatory status, whose role in AF has recently drawn attention, particularly in persistent AF population.
|
28295609 |
2017 |
Atrial Fibrillation
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Galectin-3 and hs-CRP plasma levels were elevated in NSTEMI patients with AF, but with differential predictive value for an unfavorable clinical outcome.
|
29118378 |
2017 |